'Daxoraxrasib'... a promising drug for treating pancreatic cancer

A promising drug that shrinks tumors by 60.7% and stops their growth in 90.2% of patients.
Translated by Alqyas from Al-Qabas — Original source
Dr. Wala’a Hafiz: In a promising medical development that could open new horizons for treating one of the most lethal and difficult cancers, preliminary results from a Phase 1/2 clinical trial showed that combining the oral drug “Daraxonrasib” with chemotherapy reduced tumors or led to their disappearance in 60.7% of patients with advanced pancreatic cancer. Tumors also became undetectable on CT scans in 8.2% of participants, while growth stopped in 90.2%. Michelle Mitchell, chief executive of Cancer Research UK, described the results as “the biggest leap forward in decades” for pancreatic cancer patients, a disease associated with low survival rates, especially after it has spread to other organs. The results do not mean a cure has been found; they still need to be confirmed in larger trials.
Higher survival rates: Among the key findings revealed by the trial is that 76.6% of patients were still alive one year after starting treatment, compared with the usual 40% to 45% among patients receiving chemotherapy alone. The study followed participants for an average of 18 months, a period during which some patients experienced no return of cancer, prompting researchers to consider whether the treatment could lead to deeper responses and prolong the period during which the disease can be controlled. However, longer studies are still needed to determine how long the drug’s effect lasts and whether tumor disappearance in some cases can translate into a complete and sustained remission for patients.
How the new drug works: Daraxonrasib belongs to the class of targeted therapies that attack specific genetic mutations linked to cancer cell growth. It works by inhibiting mutations in the KRAS gene, present in most cases of pancreatic cancer, which play a key role in stimulating tumor growth. The treatment concept is based on binding to these mutations and disrupting the signals that drive cancer cells to grow, thereby helping to limit tumor progression. This mechanism gains additional importance because KRAS mutations are not limited to pancreatic cancer; they are also found in other types of cancer, opening the door to studying the potential use of this therapeutic approach for other tumors carrying the same mutations.
Closest to a cure: For his part, Dr. Wongki Park, a medical oncologist specializing in gastrointestinal cancers at Memorial Sloan Kettering Cancer Center in New York, who presented the trial results, said the findings represent an exceptional advance in managing patients whose pancreatic cancer has spread. Park described the results as “the closest thing to a cure,” noting that he had never before seen such a high number of tumors disappear in patients with cancer that had spread to other organs. He added, explaining: “The average follow-up period was 18 months. Imagine the disease disappearing completely on CT scans after an average of 18 months; that is as close to complete remission as it gets. It is amazing.” Commenting on treatment responses, he clarified that researchers are beginning to observe not only an increased rate of tumor response to treatment but also deeper responses, with the duration of disease control approaching double, which could eventually translate into longer survival for patients.
“The biggest leap we have seen in treatment,” said Michelle Mitchell, chief executive of Cancer Research UK, noting that the results represent the most significant advance in pancreatic cancer therapy in decades and could offer real hope to people facing one of the most lethal and difficult-to-treat forms of cancer. She added that these findings raise the promising possibility that this development could pave the way in the future for treating other cancers that carry KRAS gene mutations. At the same time, she stressed the need for further trials before assessing whether the treatment could be used within the UK’s National Health Service, emphasizing that pancreatic cancer survival rates remain very low despite this progress.
Despite the encouraging results, doctors maintain that the drug cannot yet be considered a curative treatment, and it remains unclear how long it can keep the disease under control or whether the responses observed in the trial will be sustained in the long term. The next step, therefore, is to conduct longer and broader studies to evaluate the durability of the results, determine the treatment’s ability to achieve complete disease control in some patients, and assess its impact on extending patients’ lives.
Symptoms of pancreatic cancer include: ● Jaundice or yellowing of the skin and eyes ● Skin itching ● Darkening of urine and pale stools ● Unexplained weight loss ● Fatigue ● Fever
On August 26, the U.S. Food and Drug Administration (FDA) approved the drug “Daraxonrasib” for patients with advanced pancreatic cancer, granting it accelerated approval. The approval was based on results from a randomized trial involving 500 patients, who were equally assigned to receive either the drug or chemotherapy, as chosen by the physician. Notable side effects observed included skin rash, stomatitis, diarrhea, and gastrointestinal disturbances.